Natalie Serkova
Concepts (702)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 36 | 2014 | 627 | 2.620 |
Why?
| | Cyclosporine | 20 | 2012 | 256 | 2.460 |
Why?
| | Immunosuppressive Agents | 23 | 2013 | 829 | 2.040 |
Why?
| | Sirolimus | 17 | 2013 | 282 | 1.650 |
Why?
| | Magnetic Resonance Imaging | 25 | 2024 | 3926 | 1.500 |
Why?
| | Piperazines | 6 | 2009 | 368 | 1.140 |
Why?
| | Pyrimidines | 8 | 2017 | 532 | 1.130 |
Why?
| | Metabolomics | 11 | 2021 | 738 | 1.050 |
Why?
| | Brain | 15 | 2026 | 2991 | 1.040 |
Why?
| | Energy Metabolism | 14 | 2019 | 930 | 1.030 |
Why?
| | Glucose | 14 | 2021 | 1053 | 1.020 |
Why?
| | Contrast Media | 6 | 2017 | 493 | 0.970 |
Why?
| | Antineoplastic Agents | 15 | 2022 | 2219 | 0.940 |
Why?
| | Animals | 104 | 2026 | 38107 | 0.840 |
Why?
| | Liver | 12 | 2020 | 1864 | 0.840 |
Why?
| | Biomarkers | 14 | 2019 | 4340 | 0.830 |
Why?
| | Neoplasms, Experimental | 3 | 2020 | 163 | 0.780 |
Why?
| | Neoplasms | 14 | 2017 | 2954 | 0.770 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2017 | 893 | 0.770 |
Why?
| | Cerebellar Neoplasms | 4 | 2025 | 169 | 0.700 |
Why?
| | Medulloblastoma | 4 | 2025 | 208 | 0.690 |
Why?
| | Reperfusion Injury | 11 | 2014 | 300 | 0.660 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1432 | 0.650 |
Why?
| | Cell Line, Tumor | 29 | 2026 | 3545 | 0.640 |
Why?
| | Rats | 31 | 2015 | 5586 | 0.620 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.610 |
Why?
| | Biomarkers, Tumor | 10 | 2020 | 1339 | 0.610 |
Why?
| | Multimodal Imaging | 1 | 2020 | 137 | 0.590 |
Why?
| | Protein Kinase Inhibitors | 10 | 2018 | 983 | 0.580 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 24 | 0.570 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 128 | 0.560 |
Why?
| | Proto-Oncogene Proteins c-myc | 4 | 2025 | 157 | 0.550 |
Why?
| | Metabolome | 5 | 2019 | 390 | 0.540 |
Why?
| | Mice | 52 | 2026 | 18297 | 0.530 |
Why?
| | Ischemic Preconditioning | 2 | 2009 | 47 | 0.510 |
Why?
| | Nanoparticles | 5 | 2024 | 523 | 0.480 |
Why?
| | Brain Neoplasms | 7 | 2026 | 1325 | 0.470 |
Why?
| | Fusion Proteins, bcr-abl | 5 | 2015 | 68 | 0.470 |
Why?
| | Phospholipids | 7 | 2010 | 215 | 0.470 |
Why?
| | Everolimus | 12 | 2013 | 112 | 0.440 |
Why?
| | Rats, Wistar | 11 | 2010 | 451 | 0.440 |
Why?
| | Hypoxia | 6 | 2015 | 1211 | 0.440 |
Why?
| | Aging | 5 | 2020 | 1996 | 0.430 |
Why?
| | Glutathione | 9 | 2023 | 369 | 0.430 |
Why?
| | Body Fluids | 5 | 2019 | 70 | 0.420 |
Why?
| | Inositol | 4 | 2021 | 26 | 0.420 |
Why?
| | Glutamine | 6 | 2013 | 110 | 0.420 |
Why?
| | Apoptosis | 15 | 2024 | 2439 | 0.400 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2013 | 6 | 0.400 |
Why?
| | Organ Specificity | 4 | 2013 | 307 | 0.400 |
Why?
| | Nephritis | 1 | 2013 | 22 | 0.400 |
Why?
| | Brain Injuries | 3 | 2014 | 499 | 0.390 |
Why?
| | Positron-Emission Tomography | 10 | 2020 | 343 | 0.390 |
Why?
| | Xenograft Model Antitumor Assays | 12 | 2025 | 930 | 0.380 |
Why?
| | Lupus Nephritis | 2 | 2011 | 67 | 0.380 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 77 | 0.370 |
Why?
| | Mitochondria | 7 | 2014 | 997 | 0.370 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 99 | 0.360 |
Why?
| | Glioma | 4 | 2024 | 425 | 0.360 |
Why?
| | Leukemia | 2 | 2018 | 246 | 0.360 |
Why?
| | Astrocytes | 5 | 2026 | 229 | 0.360 |
Why?
| | Humans | 78 | 2026 | 146342 | 0.360 |
Why?
| | Blood-Brain Barrier | 3 | 2024 | 169 | 0.350 |
Why?
| | Metabolism | 3 | 2017 | 44 | 0.340 |
Why?
| | Infratentorial Neoplasms | 2 | 2024 | 69 | 0.330 |
Why?
| | Placenta | 3 | 2009 | 794 | 0.330 |
Why?
| | Disease Models, Animal | 16 | 2023 | 4580 | 0.330 |
Why?
| | Reactive Oxygen Species | 5 | 2013 | 610 | 0.330 |
Why?
| | Oxidative Stress | 5 | 2010 | 1369 | 0.330 |
Why?
| | Cell Proliferation | 14 | 2025 | 2502 | 0.330 |
Why?
| | Myocardium | 3 | 2013 | 948 | 0.320 |
Why?
| | Time Factors | 12 | 2013 | 7109 | 0.320 |
Why?
| | Benzamides | 6 | 2009 | 226 | 0.320 |
Why?
| | Kidney | 7 | 2023 | 1498 | 0.320 |
Why?
| | Kidney Diseases | 2 | 2020 | 428 | 0.310 |
Why?
| | Ependymoma | 2 | 2024 | 177 | 0.300 |
Why?
| | Liver Diseases | 2 | 2010 | 304 | 0.300 |
Why?
| | Diagnostic Imaging | 2 | 2011 | 340 | 0.300 |
Why?
| | Molecular Probes | 1 | 2009 | 33 | 0.290 |
Why?
| | Seizures | 1 | 2013 | 489 | 0.290 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 447 | 0.290 |
Why?
| | Liver Transplantation | 2 | 2007 | 751 | 0.290 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.290 |
Why?
| | Silymarin | 4 | 2016 | 147 | 0.290 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 299 | 0.280 |
Why?
| | Drug Monitoring | 3 | 2013 | 399 | 0.280 |
Why?
| | Prostatic Neoplasms | 5 | 2016 | 972 | 0.280 |
Why?
| | Lactic Acid | 7 | 2013 | 295 | 0.280 |
Why?
| | Complement C3b | 2 | 2023 | 30 | 0.280 |
Why?
| | Spermine | 1 | 2008 | 29 | 0.270 |
Why?
| | K562 Cells | 4 | 2009 | 93 | 0.270 |
Why?
| | Citric Acid | 1 | 2008 | 33 | 0.270 |
Why?
| | Adenosine Triphosphate | 6 | 2009 | 494 | 0.260 |
Why?
| | Graft Rejection | 5 | 2010 | 516 | 0.260 |
Why?
| | Hibernation | 2 | 2014 | 82 | 0.260 |
Why?
| | Adaptation, Physiological | 2 | 2009 | 568 | 0.260 |
Why?
| | Drug Design | 2 | 2007 | 180 | 0.260 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 563 | 0.250 |
Why?
| | Signal Transduction | 12 | 2026 | 5246 | 0.250 |
Why?
| | Kidney Transplantation | 4 | 2010 | 735 | 0.250 |
Why?
| | Prostate | 1 | 2008 | 159 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2786 | 0.250 |
Why?
| | Creatine | 3 | 2021 | 63 | 0.240 |
Why?
| | Altitude | 3 | 2009 | 469 | 0.240 |
Why?
| | Choline | 2 | 2009 | 136 | 0.240 |
Why?
| | Liver Failure | 1 | 2007 | 79 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 11 | 2015 | 2537 | 0.240 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2026 | 38 | 0.240 |
Why?
| | Drug Therapy | 1 | 2006 | 85 | 0.230 |
Why?
| | Pneumonia | 2 | 2011 | 635 | 0.230 |
Why?
| | Interleukin-1beta | 1 | 2008 | 397 | 0.230 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2026 | 93 | 0.230 |
Why?
| | Dietary Supplements | 3 | 2023 | 587 | 0.230 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2026 | 59 | 0.230 |
Why?
| | Nanomedicine | 2 | 2024 | 47 | 0.230 |
Why?
| | Transcription, Genetic | 4 | 2025 | 1432 | 0.230 |
Why?
| | Blotting, Western | 6 | 2019 | 1177 | 0.230 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2003 | 140 | 0.230 |
Why?
| | Male | 47 | 2024 | 73396 | 0.230 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2016 | 52 | 0.220 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 49 | 0.220 |
Why?
| | Neovascularization, Pathologic | 4 | 2018 | 287 | 0.220 |
Why?
| | Colorectal Neoplasms | 4 | 2018 | 874 | 0.220 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 32 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Protein Kinases | 2 | 2004 | 311 | 0.220 |
Why?
| | Macrolides | 2 | 2013 | 68 | 0.220 |
Why?
| | Sex Characteristics | 1 | 2010 | 801 | 0.210 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 429 | 0.210 |
Why?
| | Drug Interactions | 6 | 2012 | 405 | 0.210 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 466 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 28 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 530 | 0.210 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 449 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 314 | 0.200 |
Why?
| | Microbubbles | 1 | 2024 | 51 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2012 | 2022 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2009 | 588 | 0.200 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 39 | 0.200 |
Why?
| | Sepsis | 4 | 2013 | 669 | 0.200 |
Why?
| | Organ Transplantation | 2 | 2004 | 244 | 0.200 |
Why?
| | TOR Serine-Threonine Kinases | 6 | 2025 | 455 | 0.200 |
Why?
| | Obesity | 3 | 2006 | 3131 | 0.200 |
Why?
| | Glycolysis | 4 | 2010 | 342 | 0.190 |
Why?
| | Autophagy | 2 | 2018 | 290 | 0.190 |
Why?
| | Receptors, Estrogen | 1 | 2026 | 406 | 0.190 |
Why?
| | Autolysis | 1 | 2003 | 3 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1224 | 0.190 |
Why?
| | Glomerulonephritis | 1 | 2023 | 46 | 0.190 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 370 | 0.180 |
Why?
| | Fatty Liver | 1 | 2005 | 252 | 0.180 |
Why?
| | Lung Transplantation | 3 | 2000 | 326 | 0.180 |
Why?
| | DNA Repair | 2 | 2024 | 255 | 0.180 |
Why?
| | Phosphates | 2 | 2001 | 175 | 0.180 |
Why?
| | Deoxycytidine | 2 | 2017 | 219 | 0.180 |
Why?
| | In Vitro Techniques | 5 | 2016 | 1041 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2013 | 178 | 0.170 |
Why?
| | Colonic Neoplasms | 3 | 2013 | 259 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.170 |
Why?
| | Carbon Isotopes | 3 | 2009 | 143 | 0.170 |
Why?
| | Mice, Nude | 8 | 2016 | 668 | 0.170 |
Why?
| | Radiation Tolerance | 1 | 2022 | 101 | 0.170 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 238 | 0.170 |
Why?
| | Specimen Handling | 1 | 2003 | 178 | 0.170 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 96 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2599 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 778 | 0.170 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.160 |
Why?
| | Tendinopathy | 1 | 2021 | 32 | 0.160 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 27 | 0.160 |
Why?
| | Lung | 8 | 2018 | 4122 | 0.160 |
Why?
| | Anticarcinogenic Agents | 2 | 2011 | 63 | 0.160 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 104 | 0.160 |
Why?
| | Mass Spectrometry | 4 | 2011 | 729 | 0.160 |
Why?
| | Heat-Shock Proteins | 3 | 2006 | 140 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 65 | 0.150 |
Why?
| | Insulin Resistance | 2 | 2019 | 1247 | 0.150 |
Why?
| | Mammary Glands, Animal | 2 | 2014 | 124 | 0.150 |
Why?
| | Particle Accelerators | 1 | 2019 | 9 | 0.150 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.150 |
Why?
| | Camptothecin | 2 | 2013 | 139 | 0.150 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 24 | 0.150 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 13 | 0.150 |
Why?
| | Osteoarthritis | 1 | 2022 | 206 | 0.150 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2022 | 218 | 0.150 |
Why?
| | Heart | 1 | 2003 | 626 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2011 | 219 | 0.150 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 82 | 0.150 |
Why?
| | Brain Chemistry | 1 | 2000 | 122 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 81 | 0.150 |
Why?
| | Lactation | 2 | 2014 | 193 | 0.150 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 89 | 0.150 |
Why?
| | Perfusion | 3 | 2009 | 255 | 0.140 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 41 | 0.140 |
Why?
| | Fatty Acids | 2 | 2015 | 460 | 0.140 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 164 | 0.140 |
Why?
| | Endoplasmic Reticulum Stress | 3 | 2014 | 120 | 0.140 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.140 |
Why?
| | Tumor Cells, Cultured | 4 | 2025 | 882 | 0.140 |
Why?
| | Inflammation | 4 | 2024 | 2919 | 0.140 |
Why?
| | Lipogenesis | 2 | 2016 | 62 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2011 | 239 | 0.140 |
Why?
| | Estrogens | 2 | 2026 | 364 | 0.140 |
Why?
| | Whey Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 444 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2018 | 33 | 0.140 |
Why?
| | Glucose Clamp Technique | 1 | 2019 | 199 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 44 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1998 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 39 | 0.130 |
Why?
| | Anilides | 1 | 2018 | 83 | 0.130 |
Why?
| | Polyenes | 1 | 1997 | 17 | 0.130 |
Why?
| | Histones | 2 | 2020 | 670 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 250 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2019 | 4118 | 0.130 |
Why?
| | Kinetics | 3 | 2009 | 1553 | 0.130 |
Why?
| | Tracheal Stenosis | 1 | 2018 | 38 | 0.130 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 747 | 0.130 |
Why?
| | Rats, Zucker | 3 | 2006 | 32 | 0.130 |
Why?
| | Acute Lung Injury | 2 | 2011 | 312 | 0.130 |
Why?
| | Mucin-1 | 1 | 2017 | 29 | 0.130 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.130 |
Why?
| | Phosphorylation | 4 | 2013 | 1724 | 0.130 |
Why?
| | Female | 29 | 2026 | 79499 | 0.130 |
Why?
| | Lactates | 3 | 2006 | 82 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 166 | 0.120 |
Why?
| | Drug Synergism | 5 | 2013 | 354 | 0.120 |
Why?
| | Neuroprotective Agents | 1 | 2018 | 146 | 0.120 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 75 | 0.120 |
Why?
| | Fibroblasts | 2 | 2016 | 1034 | 0.120 |
Why?
| | Quinazolines | 2 | 2008 | 267 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2019 | 508 | 0.120 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.120 |
Why?
| | Macrophages | 3 | 2019 | 1532 | 0.120 |
Why?
| | Tissue Extracts | 2 | 2009 | 19 | 0.120 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 57 | 0.120 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2013 | 21 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2017 | 195 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 87 | 0.120 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 61 | 0.120 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 70 | 0.120 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 944 | 0.120 |
Why?
| | Transcription Factors | 5 | 2014 | 1730 | 0.120 |
Why?
| | Creatinine | 4 | 2005 | 511 | 0.120 |
Why?
| | Folic Acid | 1 | 2017 | 197 | 0.120 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2016 | 194 | 0.110 |
Why?
| | Lipid Peroxidation | 3 | 2006 | 168 | 0.110 |
Why?
| | Flow Cytometry | 2 | 2010 | 1163 | 0.110 |
Why?
| | Blood Glucose | 4 | 2019 | 2360 | 0.110 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2018 | 188 | 0.110 |
Why?
| | Fluorouracil | 2 | 2024 | 231 | 0.110 |
Why?
| | Liver Neoplasms | 2 | 2020 | 776 | 0.110 |
Why?
| | Neuroglia | 1 | 1996 | 177 | 0.110 |
Why?
| | Drug Delivery Systems | 3 | 2024 | 377 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 861 | 0.110 |
Why?
| | Pyrazoles | 2 | 2010 | 517 | 0.110 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 348 | 0.110 |
Why?
| | Methylamines | 2 | 2005 | 39 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.110 |
Why?
| | Hypothermia, Induced | 2 | 2006 | 96 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Lipid Metabolism | 4 | 2019 | 533 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2018 | 441 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 11 | 0.110 |
Why?
| | Brain Concussion | 1 | 2023 | 660 | 0.110 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2005 | 97 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1215 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2023 | 740 | 0.110 |
Why?
| | Models, Animal | 2 | 2009 | 387 | 0.100 |
Why?
| | Homeostasis | 1 | 2018 | 646 | 0.100 |
Why?
| | Ferric Compounds | 1 | 2014 | 55 | 0.100 |
Why?
| | ras Proteins | 2 | 2013 | 148 | 0.100 |
Why?
| | Rats, Inbred Lew | 4 | 2010 | 105 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1957 | 0.100 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.100 |
Why?
| | Leukotrienes | 1 | 2014 | 28 | 0.100 |
Why?
| | CRISPR-Cas Systems | 2 | 2025 | 163 | 0.100 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2014 | 34 | 0.100 |
Why?
| | Convulsants | 1 | 2013 | 8 | 0.100 |
Why?
| | Dextrans | 2 | 2014 | 83 | 0.100 |
Why?
| | Kainic Acid | 1 | 2013 | 33 | 0.100 |
Why?
| | Pyridines | 1 | 2018 | 610 | 0.100 |
Why?
| | NAD | 2 | 2004 | 80 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 44 | 0.100 |
Why?
| | Treatment Outcome | 9 | 2024 | 11821 | 0.100 |
Why?
| | Urothelium | 1 | 2013 | 33 | 0.100 |
Why?
| | Brain Edema | 1 | 2013 | 63 | 0.100 |
Why?
| | Indoles | 2 | 2015 | 511 | 0.100 |
Why?
| | Azoxymethane | 1 | 2013 | 18 | 0.100 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1244 | 0.100 |
Why?
| | Cell Survival | 4 | 2016 | 1105 | 0.100 |
Why?
| | Unfolded Protein Response | 1 | 2013 | 58 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 29 | 0.100 |
Why?
| | Disease Progression | 6 | 2026 | 2867 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2418 | 0.100 |
Why?
| | Neurons | 2 | 2026 | 1668 | 0.090 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 592 | 0.090 |
Why?
| | Prognosis | 4 | 2017 | 4351 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 974 | 0.090 |
Why?
| | Equipment Design | 2 | 2019 | 520 | 0.090 |
Why?
| | Phytic Acid | 1 | 2012 | 35 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2015 | 220 | 0.090 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 109 | 0.090 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 158 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2921 | 0.090 |
Why?
| | Thiophenes | 1 | 2013 | 117 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Reference Values | 3 | 2019 | 796 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1468 | 0.090 |
Why?
| | Image Enhancement | 2 | 2010 | 198 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 253 | 0.090 |
Why?
| | Shock, Hemorrhagic | 1 | 2014 | 195 | 0.090 |
Why?
| | Pregnancy | 6 | 2019 | 7230 | 0.090 |
Why?
| | Mice, Transgenic | 6 | 2015 | 2134 | 0.090 |
Why?
| | Insulin | 3 | 2019 | 2525 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 116 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 616 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 191 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2010 | 76 | 0.090 |
Why?
| | RNA Polymerase II | 2 | 2025 | 347 | 0.080 |
Why?
| | Temperature | 3 | 2014 | 635 | 0.080 |
Why?
| | Isotope Labeling | 1 | 2012 | 82 | 0.080 |
Why?
| | Calcineurin | 1 | 2012 | 105 | 0.080 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 598 | 0.080 |
Why?
| | Tissue Distribution | 2 | 2003 | 334 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 194 | 0.080 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 42 | 0.080 |
Why?
| | Boronic Acids | 1 | 2011 | 37 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2019 | 3416 | 0.080 |
Why?
| | Glioblastoma | 1 | 2014 | 350 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2019 | 1135 | 0.080 |
Why?
| | Models, Biological | 5 | 2013 | 1761 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 209 | 0.080 |
Why?
| | Tacrolimus | 1 | 2012 | 192 | 0.080 |
Why?
| | Nucleotides | 2 | 2017 | 128 | 0.080 |
Why?
| | Sciuridae | 2 | 2014 | 152 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 2 | 2014 | 576 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 103 | 0.080 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1512 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2011 | 191 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 162 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 384 | 0.080 |
Why?
| | Cell Movement | 3 | 2026 | 951 | 0.080 |
Why?
| | Complement C3-C5 Convertases | 1 | 2010 | 22 | 0.080 |
Why?
| | Hydroxybutyrates | 2 | 2010 | 15 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 94 | 0.080 |
Why?
| | Electroencephalography | 1 | 2013 | 576 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 762 | 0.080 |
Why?
| | Cricetulus | 1 | 2010 | 115 | 0.080 |
Why?
| | CHO Cells | 1 | 2010 | 167 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2010 | 55 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 76 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 296 | 0.070 |
Why?
| | Epigenomics | 2 | 2020 | 124 | 0.070 |
Why?
| | Adult | 10 | 2013 | 41087 | 0.070 |
Why?
| | Analysis of Variance | 2 | 2010 | 1298 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2014 | 559 | 0.070 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 238 | 0.070 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 702 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2015 | 636 | 0.070 |
Why?
| | Ribose | 1 | 2009 | 21 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 108 | 0.070 |
Why?
| | Mice, Knockout | 5 | 2020 | 3125 | 0.070 |
Why?
| | Cell Extracts | 1 | 2009 | 19 | 0.070 |
Why?
| | Dinoprost | 1 | 2009 | 51 | 0.070 |
Why?
| | Intestine, Small | 1 | 2010 | 160 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 76 | 0.070 |
Why?
| | Percussion | 1 | 2008 | 2 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 124 | 0.070 |
Why?
| | Deoxyglucose | 1 | 2009 | 51 | 0.070 |
Why?
| | Surgical Equipment | 1 | 2008 | 8 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 224 | 0.070 |
Why?
| | Mutation | 3 | 2020 | 4093 | 0.070 |
Why?
| | Receptor, ErbB-3 | 1 | 2008 | 48 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 330 | 0.070 |
Why?
| | Macaca fascicularis | 4 | 2000 | 70 | 0.070 |
Why?
| | Sulfonamides | 2 | 2011 | 594 | 0.070 |
Why?
| | Systems Biology | 1 | 2009 | 68 | 0.070 |
Why?
| | Alanine | 2 | 2013 | 171 | 0.070 |
Why?
| | Complement C3d | 2 | 2023 | 67 | 0.070 |
Why?
| | Body Weight | 4 | 2012 | 968 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 1075 | 0.070 |
Why?
| | Oxygen | 2 | 2010 | 997 | 0.060 |
Why?
| | Protein Transport | 1 | 2009 | 443 | 0.060 |
Why?
| | Lymphocytes | 1 | 2009 | 379 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1421 | 0.060 |
Why?
| | Area Under Curve | 1 | 2008 | 335 | 0.060 |
Why?
| | Triglycerides | 2 | 2010 | 527 | 0.060 |
Why?
| | Critical Illness | 2 | 2011 | 908 | 0.060 |
Why?
| | Heart-Assist Devices | 1 | 2013 | 572 | 0.060 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.060 |
Why?
| | Tritium | 1 | 2006 | 64 | 0.060 |
Why?
| | Oxidative Phosphorylation | 2 | 2005 | 212 | 0.060 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 117 | 0.060 |
Why?
| | MicroRNAs | 1 | 2013 | 699 | 0.060 |
Why?
| | Nitrogen | 1 | 2007 | 125 | 0.060 |
Why?
| | Up-Regulation | 2 | 2006 | 841 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 244 | 0.060 |
Why?
| | Age Factors | 2 | 2011 | 3347 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 228 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2013 | 217 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 585 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 559 | 0.060 |
Why?
| | Piperidines | 1 | 2007 | 225 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 6034 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 17 | 0.060 |
Why?
| | Heat-Shock Response | 1 | 2006 | 78 | 0.060 |
Why?
| | Medical Oncology | 1 | 2009 | 345 | 0.060 |
Why?
| | Liver Failure, Acute | 1 | 2006 | 78 | 0.060 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.060 |
Why?
| | Betaine | 1 | 2005 | 66 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 1982 | 0.050 |
Why?
| | Survival Rate | 3 | 2019 | 2092 | 0.050 |
Why?
| | Deuterium | 1 | 2005 | 101 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2012 | 850 | 0.050 |
Why?
| | Glutamic Acid | 2 | 2010 | 255 | 0.050 |
Why?
| | Methionine | 1 | 2005 | 160 | 0.050 |
Why?
| | Reference Standards | 2 | 2019 | 176 | 0.050 |
Why?
| | Glutamates | 1 | 2004 | 66 | 0.050 |
Why?
| | Lung Injury | 1 | 2008 | 263 | 0.050 |
Why?
| | Seasons | 1 | 2007 | 540 | 0.050 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 8 | 0.050 |
Why?
| | Heart Rate | 2 | 2009 | 846 | 0.050 |
Why?
| | Free Radical Scavengers | 1 | 2004 | 81 | 0.050 |
Why?
| | Uric Acid | 1 | 2005 | 167 | 0.050 |
Why?
| | Dacarbazine | 2 | 2014 | 98 | 0.050 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 31 | 0.050 |
Why?
| | Biological Transport | 2 | 2015 | 424 | 0.050 |
Why?
| | Cholesterol | 1 | 2005 | 411 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1792 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 105 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 67 | 0.050 |
Why?
| | Hot Temperature | 1 | 2006 | 396 | 0.050 |
Why?
| | Proteins | 1 | 2009 | 1022 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2003 | 197 | 0.050 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2004 | 50 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 633 | 0.050 |
Why?
| | Cardiac Output | 1 | 2003 | 176 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 139 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2003 | 134 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 30 | 0.050 |
Why?
| | Drug Carriers | 1 | 2024 | 138 | 0.050 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 70 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 217 | 0.050 |
Why?
| | Lipids | 2 | 2021 | 714 | 0.050 |
Why?
| | Necrosis | 3 | 2010 | 243 | 0.050 |
Why?
| | Aged | 5 | 2013 | 26432 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 194 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 166 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 107 | 0.050 |
Why?
| | Rupture | 1 | 2022 | 91 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2002 | 67 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 41 | 0.040 |
Why?
| | Child | 4 | 2024 | 22693 | 0.040 |
Why?
| | Liposomes | 1 | 2024 | 269 | 0.040 |
Why?
| | Reperfusion | 1 | 2002 | 53 | 0.040 |
Why?
| | Anterior Cruciate Ligament | 1 | 2022 | 103 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2009 | 927 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2010 | 959 | 0.040 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.040 |
Why?
| | Tumor Burden | 2 | 2014 | 326 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2013 | 193 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 88 | 0.040 |
Why?
| | Succinic Acid | 2 | 2013 | 46 | 0.040 |
Why?
| | Tibia | 1 | 2022 | 177 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2001 | 85 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 121 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 457 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1036 | 0.040 |
Why?
| | Random Allocation | 3 | 2006 | 366 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 245 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 29 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 122 | 0.040 |
Why?
| | Middle Aged | 6 | 2016 | 36619 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 86 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 385 | 0.040 |
Why?
| | Tunica Intima | 1 | 2000 | 80 | 0.040 |
Why?
| | Ligands | 2 | 2012 | 678 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 128 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2001 | 195 | 0.040 |
Why?
| | Phenotype | 3 | 2016 | 3206 | 0.040 |
Why?
| | Heart Failure | 1 | 2013 | 2329 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2013 | 759 | 0.040 |
Why?
| | Sheep, Domestic | 1 | 2019 | 33 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 345 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 360 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 84 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 790 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1378 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 453 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 416 | 0.030 |
Why?
| | Mifepristone | 1 | 2018 | 45 | 0.030 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2018 | 18 | 0.030 |
Why?
| | Salivary Glands | 1 | 2018 | 36 | 0.030 |
Why?
| | Radiology, Interventional | 1 | 2019 | 49 | 0.030 |
Why?
| | Anthropometry | 1 | 2019 | 204 | 0.030 |
Why?
| | Knee Joint | 1 | 2022 | 453 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2004 | 609 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 303 | 0.030 |
Why?
| | NF-kappa B | 2 | 2013 | 674 | 0.030 |
Why?
| | Breast | 1 | 2019 | 155 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1712 | 0.030 |
Why?
| | Amino Acids | 1 | 2002 | 515 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2019 | 160 | 0.030 |
Why?
| | Citric Acid Cycle | 1 | 1997 | 58 | 0.030 |
Why?
| | Cell Size | 1 | 1997 | 95 | 0.030 |
Why?
| | Robotics | 1 | 2019 | 89 | 0.030 |
Why?
| | Digoxin | 1 | 2017 | 27 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 562 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 55 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2675 | 0.030 |
Why?
| | Cytosol | 1 | 1997 | 215 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 267 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 74 | 0.030 |
Why?
| | Cysteine | 1 | 2018 | 210 | 0.030 |
Why?
| | Rabbits | 1 | 2018 | 651 | 0.030 |
Why?
| | Aorta | 1 | 2000 | 440 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 39 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 295 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 176 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 42 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 511 | 0.030 |
Why?
| | Membrane Lipids | 1 | 1996 | 81 | 0.030 |
Why?
| | Heat Shock Transcription Factors | 2 | 2006 | 22 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 122 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 467 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 249 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2015 | 21 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 990 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 57 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 49 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2015 | 55 | 0.030 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 5 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 712 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 888 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 75 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 157 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 335 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10921 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 462 | 0.030 |
Why?
| | Chlorobenzenes | 1 | 2014 | 18 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 210 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 198 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 222 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 310 | 0.030 |
Why?
| | Maze Learning | 1 | 2014 | 106 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 504 | 0.020 |
Why?
| | Recovery of Function | 1 | 2018 | 725 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 186 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 290 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1160 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2013 | 87 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2013 | 73 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.020 |
Why?
| | Software | 1 | 2019 | 676 | 0.020 |
Why?
| | Mice, Inbred A | 1 | 2013 | 47 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 57 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 6 | 0.020 |
Why?
| | Catalysis | 1 | 2014 | 304 | 0.020 |
Why?
| | Somatomedins | 1 | 2013 | 28 | 0.020 |
Why?
| | Particle Size | 1 | 2014 | 386 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 76 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 148 | 0.020 |
Why?
| | Vacuoles | 1 | 2013 | 36 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 164 | 0.020 |
Why?
| | Mitogens | 1 | 2013 | 55 | 0.020 |
Why?
| | Cell Shape | 1 | 2013 | 56 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 472 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 197 | 0.020 |
Why?
| | Tissue Donors | 2 | 2010 | 425 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 39 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 117 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 197 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 165 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3712 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 157 | 0.020 |
Why?
| | Carcinogens | 1 | 2013 | 112 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 111 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 313 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 174 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2791 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1068 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 125 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2014 | 206 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 517 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 288 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2011 | 37 | 0.020 |
Why?
| | Self Administration | 1 | 2012 | 121 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 200 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4595 | 0.020 |
Why?
| | Sucrose | 1 | 2012 | 113 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 993 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 54 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 752 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 250 | 0.020 |
Why?
| | Nestin | 1 | 2010 | 19 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2010 | 34 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 231 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2011 | 129 | 0.020 |
Why?
| | Urethane | 1 | 2010 | 43 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 319 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 294 | 0.020 |
Why?
| | Neutrophils | 2 | 2006 | 1133 | 0.020 |
Why?
| | Receptors, Complement 3d | 1 | 2011 | 150 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 17 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 363 | 0.020 |
Why?
| | Adenine | 1 | 2013 | 339 | 0.020 |
Why?
| | HT29 Cells | 1 | 2010 | 37 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 496 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 156 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 240 | 0.020 |
Why?
| | Hydrogen | 1 | 2010 | 73 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 120 | 0.020 |
Why?
| | Limit of Detection | 1 | 2009 | 92 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 133 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2010 | 240 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 193 | 0.020 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 385 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 214 | 0.020 |
Why?
| | Portal Vein | 1 | 2010 | 123 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 104 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 41 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 56 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 432 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 227 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 595 | 0.020 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2008 | 42 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2009 | 192 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 614 | 0.020 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 35 | 0.020 |
Why?
| | Dura Mater | 1 | 2008 | 41 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1879 | 0.020 |
Why?
| | Craniotomy | 1 | 2008 | 83 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 8391 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 989 | 0.020 |
Why?
| | Pressure | 1 | 2008 | 221 | 0.020 |
Why?
| | Drug Discovery | 1 | 2009 | 154 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 545 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 630 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 597 | 0.020 |
Why?
| | Carcinoma | 1 | 2008 | 225 | 0.020 |
Why?
| | United States | 1 | 2024 | 16136 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2006 | 86 | 0.010 |
Why?
| | Peroxidase | 1 | 2006 | 168 | 0.010 |
Why?
| | Risk | 1 | 2008 | 920 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2006 | 151 | 0.010 |
Why?
| | Organ Size | 1 | 2006 | 465 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1412 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2005 | 13 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11913 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3647 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2081 | 0.010 |
Why?
| | Quercetin | 1 | 2005 | 20 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2008 | 485 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1888 | 0.010 |
Why?
| | Dietary Fats | 1 | 2006 | 307 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 666 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| | Raffinose | 1 | 2003 | 29 | 0.010 |
Why?
| | Computational Biology | 1 | 2009 | 678 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2010 | 925 | 0.010 |
Why?
| | Allopurinol | 1 | 2003 | 70 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2003 | 47 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 992 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 369 | 0.010 |
Why?
| | Cell Membrane | 1 | 2006 | 701 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 31 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2244 | 0.010 |
Why?
| | Adenosine | 1 | 2003 | 256 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 175 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 372 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1463 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 861 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 396 | 0.010 |
Why?
| | Automation | 1 | 2000 | 104 | 0.010 |
Why?
| | Microchemistry | 1 | 2000 | 19 | 0.010 |
Why?
| | Calibration | 1 | 2000 | 154 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Emulsions | 1 | 2000 | 58 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 573 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 96 | 0.010 |
Why?
| | Blood | 1 | 2000 | 107 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 355 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1827 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 8123 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2000 | 386 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 999 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 663 | 0.010 |
Why?
| | Biopsy | 1 | 2000 | 1075 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1998 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|